Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Pain Med ; 18(2): 294-306, 2017 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-28204792

RESUMO

Objective: To assess prevalence rates and correlates of problematic use of prescription opioids and medicinal cannabis (MC) among patients receiving treatment for chronic pain. Design: Cross-sectional study. Setting: Two leading pain clinics in Israel. Subjects: Our sample included 888 individuals receiving treatment for chronic pain, of whom 99.4% received treatment with prescription opioids or MC. Methods: Problematic use of prescription opioids and MC was assessed using DSM-IV criteria, Portenoy's Criteria (PC), and the Current Opioid Misuse Measure (COMM) questionnaire. Additional sociodemographic and clinical correlates of problematic use were also assessed. Results: Among individuals treated with prescription opioids, prevalence of problematic use of opioids according to DSM-IV, PC, and COMM was 52.6%, 17.1%, and 28.7%, respectively. Among those treated with MC, prevalence of problematic use of cannabis according to DSM-IV and PC was 21.2% and 10.6%, respectively. Problematic use of opioids and cannabis was more common in individuals using medications for longer periods of time, reporting higher levels of depression and anxiety, and using alcohol or drugs. Problematic use of opioids was associated with higher self-reported levels of pain, and problematic use of cannabis was more common among individuals using larger amounts of MC. Conclusions: Problematic use of opioids is common among chronic pain patients treated with prescription opioids and is more prevalent than problematic use of cannabis among those receiving MC. Pain patients should be screened for risk factors for problematic use before initiating long-term treatment for pain-control.


Assuntos
Dor Crônica/tratamento farmacológico , Abuso de Maconha/epidemiologia , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Adulto , Idoso , Analgésicos Opioides/uso terapêutico , Estudos Transversais , Feminino , Humanos , Israel/epidemiologia , Masculino , Maconha Medicinal/uso terapêutico , Pessoa de Meia-Idade , Prevalência , Adulto Jovem
2.
Pain Res Manag ; 16(3): 197-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21766071

RESUMO

Bowel dysfunction, mainly constipation, is a well-known and anticipated side effect of opioids. The physician prescribing an opioid frequently confronts the challenge of preventing and treating bowel dysfunction. Different strategies have emerged for managing opioid-induced constipation. These strategies include physical activity, maintaining adequate fluid intake, adhering to regular daily bowel habits, using laxatives and other anticonstipation medications and, recently, using a peripheral opioid antagonist, either as a separate drug or in the form of an opioid agonistantagonist combination pill. What options exist for the physician when a patient receiving opioids complains of diarrhea, cramps and bloating, rather than the expected constipation? The present article describes a possible cause of opioid-induced diarrhea and strategies for management.


Assuntos
Analgésicos Opioides/efeitos adversos , Diarreia/induzido quimicamente , Morfina/efeitos adversos , Oxicodona/efeitos adversos , Diarreia/prevenção & controle , Relação Dose-Resposta a Droga , Humanos , Lactose/administração & dosagem , Dor/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA